


AMENDMENTS TO THE CLAIMS

Claims:

1.(Amended) A compound of formula I,



wherein

NRR₁ is attached at the 5- or 6-position of the furopyridine ring;

R is hydrogen, C₁-C₄ alkyl, or COR₂;

R₁ is (CH₂)_nAr, CH₂CH=CHAr, or CH₂C≡CAr;

n is 0 to 3;

A is N- or NO;

Ar is a 5- or 6-membered aromatic or heteroaromatic ring which contains zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms; or:

an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms; any of which may optionally be substituted with one to two substituents independently selected from: halogen, trifluoromethyl, or C₁-C₄ alkyl;

R₂ is hydrogen, C₁-C₄ alkyl; C₁-C₄ alkoxy; or phenyl ring optionally substituted with one to three of the following substituents: halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, OH, OC₁-C₄ alkyl, CO₂R₅, -CN, -NO₂, -NR₃R₄, or -CF₃;

R₃, R₄ and R₅ are independently hydrogen; C₁-C₄ alkyl; or phenyl ring optionally substituted with one to three of the following substituents: halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, OH, OC₁-C₄ alkyl, -CN, -NO₂, or -CF₃;
or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

2-3. (Cancelled)

4. (Amended) A compound according to claim ~~1-2~~, wherein R_1 is $CH_2CH=CHAr$; or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

5. (Amended) A compound according to claim ~~1-2~~, wherein R_1 is $CH_2C\equiv CAr$; or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

6. (Cancelled)

7. (Amended) A compound according to any one of claims 1, 4 or 5, wherein Ar is selected from the group: 1-, or 2-naphthyl; 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl; 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolyl; 2-, 4-, 5-, 6-, or 7-benzoxazolyl; and 3-, 4-, 5-, 6-, or 7-benzisoxazolyl; or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

8. (Amended) A compound according to any one of claims 1, 4 or 5 ~~to 6~~, wherein R_3 , R_4 and R_5 are independently hydrogen, or C_1 - C_4 alkyl; or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

9-10.(Cancelled)

11. (Amended) A compound according to any one of claims 1, 4, 5, 7 or 8, wherein Ar is an heteroaromatic ring.

12. (Amended) A compound according to any one of claims 1, 4, 5, 7 or 8 wherein n is 1; R is hydrogen and Ar is an heteroaromatic ring.

13. (Cancelled)

14. (Amended) A compound according to claim 1, said compound being:
R-(-)-5'-(3-Pyridylmethyl) aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-(4-Pyridylmethyl) aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

15-43. (Cancelled)